One dose of Cefo-perazone Sulbactum — Competitive Intelligence Brief

One dose of Cefo-perazone Sulbactum (One dose of Cefo-perazone Sulbactum) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamases Infectious Disease Small molecule

Target snapshot

One dose of Cefo-perazone Sulbactum (One dose of Cefo-perazone Sulbactum) — Asian Institute of Gastroenterology, India. Cefoperazone/sulbactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
One dose of Cefo-perazone Sulbactum TARGET	One dose of Cefo-perazone Sulbactum	Asian Institute of Gastroenterology, India	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
cefoperazone sodium and sulbactam sodium	cefoperazone sodium and sulbactam sodium	Yung Shin Pharm. Ind. Co., Ltd.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; beta-lactamases
amoxicillin/clavulanate potassium 1gm	amoxicillin/clavulanate potassium 1gm	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Piperacillin / Tazobactam Injection	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
high dose amoxicillin/clavulanate	high dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase
Piperacillin, Tazobactam Drug Combination	Piperacillin, Tazobactam Drug Combination	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase enzymes
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class